BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
4 reports, 2 independent
Updated Sep 12
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BioXcel Therapeutics files for Chapter 11 bankruptcy in Delaware.1 source
BioXcel Therapeutics' drug was approved by the FDA, coinciding with results announced from New Haven.1 source
Keep exploring
The entities involved
Related events
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- The FDA recommended advancement for a new drug application submitted by a company.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA approval enables commercial opportunity involving CBRE Group.
Coverage
Newest first; wire copies grouped- hartfordbusiness.com
- GlobeNewswireBioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 20